Phase II study of nab-paclitaxel for relapsed non-small cell lung cancer (NLCTG1302)
Phase 2
- Conditions
- non small cell lung cancer
- Registration Number
- JPRN-UMIN000012343
- Lead Sponsor
- iigata Lung Cancer Treatment Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 65
Inclusion Criteria
Not provided
Exclusion Criteria
1)History of paclitaxel treatment 2)Severe complications 1:Type 2 DM treated with insulin injection 2:Symptomatic congestive heart failure or unstable angina or problematic arrhythmia or history of acute myocardial infarction within one year 3:Interstitial pneumonia or active radiation pneumonia or drug-induced pneumonia 3)Problematic infection 4)History of active double cancer 5)Severe drug allergy 6)No intention to birth control 7)Unstable psychic disorder 8)Decision of ineligibility by a physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method Safety, Progression free survival, Disease control rate, Overall survival, Evaluation of sensory neuropathy using PNQ score